

Flow Cytometry High Impact Immunology Research Publications 2024–2025

ZE5 Cell Analyzer Publications

Arya SB et al. (2025).

Neutrophils secrete exosome-associated DNA to resolve sterile acute inflammation.

Nat Cell Biol 27, 931–947.

pubmed.ncbi.nlm.nih.gov/40404894

Bushnell GG et al. (2024).

Natural killer cell regulation of breast cancer stem cells mediates metastatic dormancy.

Cancer Res 84, 3337–3353.

pubmed.ncbi.nlm.nih.gov/39106452

Chen L et al. (2025).

Zonated copper-driven breast cancer progression countered by a copper-depleting nanoagent for immune and metabolic reprogramming.

Adv Sci (Weinh) 12, e2412434.

pubmed.ncbi.nlm.nih.gov/40270472

Chen YH et al. (2025).

Rewilding catalyzes maturation of the humoral immune system.

Sci Adv 11, eads2364.

pubmed.ncbi.nlm.nih.gov/40053586

Cohen-Dvashi H et al. (2025).

Metal-induced conformational changes in the Sabiá virus spike complex.

Nat Microbiol 10, 2221–2230.

pubmed.ncbi.nlm.nih.gov/40751015



Dijkstra KK et al. (2025).

Subclonal immune evasion in non-small cell lung cancer.
Cancer Cell 43, 1833–1849.e10.
pubmed.ncbi.nlm.nih.gov/40614739

Gellert J et al. (2024).

Tumoral interferon beta induces an immune-stimulatory phenotype in tumor-associated macrophages in melanoma brain metastases.
Cancer Res Commun 4, 2189–2202.
pubmed.ncbi.nlm.nih.gov/39056192

Griffith BD et al. (2026).

Aryl hydrocarbon receptor ligands drive pancreatic cancer initiation and progression through protumorigenic T cell polarization.
Cancer Discov, 114–134.
pubmed.ncbi.nlm.nih.gov/40905825

Han K et al. (2024).

Inulin-gel-based oral immunotherapy remodels the small intestinal microbiome and suppresses food allergy.
Nat Mater 23, 1444–1455.
pubmed.ncbi.nlm.nih.gov/38977883/

Herate C et al. (2025).

Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model.
Nat Commun 16, 7306.
pubmed.ncbi.nlm.nih.gov/40775237

Hoy, CK et al. (2024).

Calprotectin impairs platelet survival in patients with primary antiphospholipid syndrome.
Arthritis Rheumatol 76, 928–935.
pubmed.ncbi.nlm.nih.gov/38225923

Li B et al. (2024).

Multi-omics approach reveals TGF- β signaling-driven senescence in periodontium stem cells.
J Adv Res 76, 387–403.
pubmed.ncbi.nlm.nih.gov/39743213/

Mohaghegh N et al. (2025).

Apigenin-loaded nanoparticles for obesity intervention through immunomodulation and adipocyte browning.
J Control Release 382, 113670.
pubmed.ncbi.nlm.nih.gov/40187647/

Oliveira L et al. (2025).

Peripheral blood CD4+ and CD8+ T cell responses to cryptococcus candidate vaccine antigens in human subjects with and without cryptococcosis.
J Infect 91, 106521.
pubmed.ncbi.nlm.nih.gov/40449806/

Panda S et al. (2024).

Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection.
Nat Commun 15, 765.
pubmed.ncbi.nlm.nih.gov/38278794/

Pereira Neto TA et al. (2025).

Highly conserved betacoronavirus sequences are broadly recognized by human T cells.
Cell 188, 5653–5665.
pubmed.ncbi.nlm.nih.gov/40774254/

Rios AV et al. (2025).

Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy.
Mol Ther 33, 5489–5504.
pubmed.ncbi.nlm.nih.gov/40842156/

Schoenfeld AJ et al. (2024).

Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors.
Cancer Discov 14, 1389–1402.
pubmed.ncbi.nlm.nih.gov/38563600/

Sun X et al. (2024).

Self-assembled STING-activating coordination nanoparticles for cancer immunotherapy and vaccine applications.
ACS Nano 18, 10439–10453.
pubmed.ncbi.nlm.nih.gov/38567994/

Walsh ZH et al. (2025).

Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment.

Cell 188, 4861–4879.e27.

pubmed.ncbi.nlm.nih.gov/40543502/

Yagi M et al. (2025).

Bivalent chromatin instructs lineage specification during hematopoiesis.

Cell 188, 4314–4331.e29.

pubmed.ncbi.nlm.nih.gov/40532700/

Yang D et al. (2024).

UBR5 promotes antiviral immunity by disengaging the transcriptional brake on RIG-I like receptors.

Nat Commun 15, 780.

pubmed.ncbi.nlm.nih.gov/38278841/

Yang S et al. (2025).

PTPN22-CD45 dual phosphatase retrograde feedback enhances TCR signaling and autoimmunity.

Sci Adv 11, eadw2568.

pubmed.ncbi.nlm.nih.gov/40911684/

Yeung ST et al. (2025).

Nerve- and airway-associated interstitial macrophages mitigate SARS-CoV-2 pathogenesis via type I interferon signalling.

Immunity 58, 1327–1342.e5.

pubmed.ncbi.nlm.nih.gov/40286790/

Zeng F et al. (2025).

Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response.

Mol Cancer 24, 110.

pubmed.ncbi.nlm.nih.gov/40205519/

Zhang Q et al. (2024).

Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma.

Theranostics 14, 892–910.

pubmed.ncbi.nlm.nih.gov/38169544/

Zong P et al. (2025).

TRPM2 overactivation drives hyperlipidemia-induced dysfunction of myeloid cells and neurovascular units.

Cell Rep Med 6, 101998.

pubmed.ncbi.nlm.nih.gov/40056905/

Visit bio-rad.com/ZE5CellAnalyzer for more information.

Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. All trademarks used herein are the property of their respective owner.

© 2026 Bio-Rad Laboratories, Inc.



**Bio-Rad
Laboratories, Inc.**

**Life Science
Group**

Website bio-rad.com **USA** 1 800 424 6723 **Australia** 61 2 9914 2800 **Austria** 00 800 00 24 67 23 **Belgium** 00 800 00 24 67 23 **Brazil** 55 11 3065 7550
Canada 1 800 361 1808 **China** 86 21 6169 8500 **Czech Republic** 00 800 00 24 67 23 **Denmark** 00 800 00 24 67 23 **Finland** 00 800 00 24 67 23
France 00 800 00 24 67 23 **Germany** 00 800 00 24 67 23 **Greece** 30 210 7774396 **Hong Kong** 852 2789 3300 **Hungary** 00 800 00 24 67 23
India 91 124 4029300 **Israel** 000 800 00 24 67 23 **Italy** 00 800 00 24 67 23 **Japan** 81 3 6361 7000 **Korea** 82 080 007 7373 **Luxembourg** 00 800 00 24 67 23
Mexico 52 55 5488 7670 **The Netherlands** 00 800 00 24 67 23 **New Zealand** 64 9 415 2280 **Norway** 00 800 00 24 67 23 **Poland** 00 800 00 24 67 23
Portugal 00 800 00 24 67 23 **Russian Federation** 7 495 721 14 04 **Singapore** 65 6415-3170 **South Africa** 27 21 531 7504 **Spain** 00 800 00 24 67 23
Sweden 00 800 00 24 67 23 **Switzerland** 00 800 00 24 67 23 **Taiwan** 886 2 2578 7189 **Thailand** 662 651 8311 **United Arab Emirates** 971 4 818 7300
United Kingdom 00 800 00 24 67 23